Common themes and challenges in hemophilia care: a multinational perspective

References

• Stonebraker JS, Bolton-Maggs PH, Soucie JM, et al. A study of variations in the reported haemophilia A prevalence around the world. Haemophilia. 2010;16(1):20–32. doi: 10.1111/j.1365-2516.2009.02127.x
   PubMed Web of Science ®Google Scholar
• Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Treatment guidelines working group on behalf of World Federation of Hemophilia. Guidelines for the management of hemophilia. Haemophilia. 2013;19:e1–e47. doi: 10.1111/j.1365-2516.2012.02909.x
   PubMed Web of Science ®Google Scholar
• Poonnoose P, Carneiro JDA, Cruickshank AL, et al. MUSFIH study group. Episodic replacement of clotting factor concentrates does not prevent bleeding or musculoskeletal damage - the MUSFIH study. Haemophilia. 2017;23(4):538–546. doi: 10.1111/hae.13242
   PubMed Web of Science ®Google Scholar
• van den Berg HM. From treatment to prevention of bleeds: what more evidence do we need? Haemophilia. 2017;23(4):494–496. doi: 10.1111/hae.13256
   PubMed Web of Science ®Google Scholar
• World Health Organization. Adherence to long-term therapies: Evidence for action. Available from: http://www.who.int/chp/knowledge/publications/adherence_full_report.pdf.
   Google Scholar
• Gringeri A, Doralt J, Valentino LA, et al. An innovative outcome-based care and procurement model of hemophilia management. Expert Rev Pharmacoecon Outcomes Res. 2016;16(3):337–345. doi: 10.1080/14737167.2016.1178066
   PubMed Web of Science ®Google Scholar
• Zappa S, McDaniel M, Marandola J, et al. Treatment trends for haemophilia A and haemophilia B in the United States: results from the 2010 practice patterns survey. Haemophilia. 2012;18:e140–e153. doi: 10.1111/j.1365-2516.2012.02770.x
   PubMed Web of Science ®Google Scholar
• Page D, Crymble S, Lawday K, et al. Penny wise, pound foolish: An assessment of Canadian Hemophilia/inherited bleeding disorder comprehensive care program services and resources. Haemophilia. 2016;22(4):531–536. doi: 10.1111/hae.12913
   PubMed Web of Science ®Google Scholar
• Institute of Medicine (US) Committee on Standards for Developing Trustworthy Clinical Practice Guidelines, Graham R, Mancher M, et al. Clinical practice guidelines we can trust. Washington (DC): National Academies Press (US); 2011; 1, Introduction. Available from: https://www.ncbi.nlm.nih.gov/books/NBK209546/.
   Google Scholar
• Pai M, Key NS, Skinner M, et al. NHF-McMaster Guideline on care models for haemophilia management. Haemophilia. 2016;22(Suppl 3):6–16. doi: 10.1111/hae.13008
   PubMed Web of Science ®Google Scholar
• Nordic Hemophilia Guidelines. Available from: http://nordhemophilia.org.
   Google Scholar
• National Ministry of Health and Social Protection (Colombia). Situación de la Hemofilia en Colombia, 2016. Registro de información para el año 2016. Cuenta de alto costo Ministerio de Salud. Available from: https://cuentadealtocosto.org/site/index.php/publicaciones#hemofilia
   Google Scholar
• Pipe SW, Kessler CM. Evidence-based guidelines support integrated disease management as the optimal model of haemophilia care. Hemophilia. 2016;22(Suppl 3):3–5. doi: 10.1111/hae.12997
   PubMed Web of Science ®Google Scholar
• Skinner MW, Soucie JM, McLaughlin K. The national haemophilia program standards, evaluation and oversight systems in the United States of America. Blood Transfusion. 2014;12(Suppl 3):e542–e548.
   PubMed Web of Science ®Google Scholar
• National Hemophilia Foundation. Comprehensive Medical Care Hemophilia Treatment 2017. Available from: https://www.hemophilia.org/Researchers-Healthcare-Providers/Comprehensive-Medical-Care-Hemophilia-Treatment-Centers.
   Google Scholar
• Medical and Scientific Advisory Council (MASAC) of the National Hemophilia Foundation. Standards and criteria for the care of persons with congenital bleeding disorders (revised April 2002). Available from: https://www.hemophilia.org/Researchers-Healthcare-Providers/Medical-and-Scientific-Advisory-Council-MASAC/MASAC-Recommendations/Standards-and-Criteria-for-the-Care-of-Persons-with-Congenital-Bleeding-Disorders.
   Google Scholar
• EAHAD Nurses Committee, Harrington C, Bedford M, et al. A European curriculum for nurses working in haemophilia. Haemophilia. 2016;22(1):103–109. doi: 10.1111/hae.12785
   PubMed Web of Science ®Google Scholar
• Colvin BT, Astermark J, Fischer K, et al. Inter Disciplinary Working Group. European principles of haemophilia care. Haemophilia. 2008;14(2):361–374. doi: 10.1111/j.1365-2516.2007.01625.x
   PubMed Web of Science ®Google Scholar
• Lindvall K, von Mackensen S, Elmståhl S, et al. Knowledge of disease and adherence in adult patients with haemophilia. Haemophilia. 2010;16(4):592–596.
   PubMed Web of Science ®Google Scholar
• O’Mahony B, Skinner MW, Noone D, et al. Assessments of outcome in haemophilia - a patient perspective. Haemophilia. 2016;22(3):e208–e209. doi: 10.1111/hae.12922
   PubMed Web of Science ®Google Scholar
• Hanley J, McKernan A, Creagh MD, et al. Musculoskeletal working party of the UKHCDO. Guidelines for the management of acute joint bleeds and chronic synovitis in haemophilia: A United Kingdom Haemophilia Centre Doctors' Organisation (UKHCDO) guideline. Haemophilia. 2017;23(4):511–520. doi: 10.1111/hae.13201
   PubMed Web of Science ®Google Scholar
• Collins PW, Blanchette VS, Fischer K, et al. rAHF-PFM Study Group. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe haemophilia A. J Thromb Haemost. 2009;7(3):413–420. doi: 10.1111/j.1538-7836.2008.03270.x
   PubMed Web of Science ®Google Scholar
• LaBresh KA, Gliklich R, Liljestrand J, et al. Using “get with the guidelines” to improve cardiovascular secondary prevention. J Comm J Qual Saf. 2003;29(10):539–550.
   PubMedGoogle Scholar
• Hassan HJ, Morfini M, Taruscio D, et al. Current status of Italian registries on inherited bleeding disorders. Blood Transf. 2014;12(Suppl 3):s576–s581.
   PubMed Web of Science ®Google Scholar
• Calvez T, Chambost H, Claeyssens-Donadel S, et al. Francecoag Network. Recombinant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A. Blood. 2014;124(23):3398–3408. doi: 10.1182/blood-2014-07-586347
   PubMed Web of Science ®Google Scholar
• Hamburg MA, Collins FS. The path to personalized medicine. N Engl J Med. 2010;363:301–304. doi: 10.1056/NEJMp1006304
   PubMed Web of Science ®Google Scholar
• Reininger AJ, Chehadeh HE. The principles of PK-tailored prophylaxis. Hämostaseologie. 2013;33(Suppl 1):S32–S35.
   PubMed Web of Science ®Google Scholar
• Ljung R, Fischer K, Carcao M, et al. INPH group. Practical considerations in choosing a factor VIII prophylaxis regimen: role of clinical phenotype and trough levels. Thromb Haemost. 2016;115(5):913–920. doi: 10.1160/TH15-08-0664
   PubMed Web of Science ®Google Scholar
• Auerswald G, Dolan G, Duffy A, et al. Pain and pain management in haemophilia. Blood Coagul Fibrinolysis. 2016;27:845–854. doi: 10.1097/MBC.0000000000000571
   PubMed Web of Science ®Google Scholar
• Stephensen D, Drechsler WI, Scott OM. Biomechanics of lower limb haemophilic arthropathy. Blood Rev. 2012;26(5):213–221. doi: 10.1016/j.blre.2012.06.003
   PubMed Web of Science ®Google Scholar
• Ceponis A, Wong-Sefidan I, Glass CS, et al. Rapid musculoskeletal ultrasound for painful episodes in adult haemophilia patients. Haemophilia. 2013;19(5):790–798. doi: 10.1111/hae.12175
   PubMed Web of Science ®Google Scholar
• Strike KL, Iorio A, Jackson S, et al. Point of care ultrasonography in haemophilia care: recommendations for training and competency evaluation. Haemophilia. 2015;21(6):828–831. doi: 10.1111/hae.12767
   PubMed Web of Science ®Google Scholar
• Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. New Engl J Med. 2007;357(6):535–544. doi: 10.1056/NEJMoa067659
   PubMed Web of Science ®Google Scholar
• National Hemophilia Foundation. MASAC Recommendations concerning prophylaxis (regular administration of clotting factor concentrate to prevent bleeding) 2016. Document 179. Available from: http://www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=57&contentid=1007.
   Google Scholar
• Feldman BM, Pai M, Rivard GE, et al. Association of Hemophilia Clinic Directors of Canada Prophylaxis Study Group. Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia primary prophylaxis study. J Thromb Haemost. 2006;4:1228–1236. doi: 10.1111/j.1538-7836.2006.01953.x
   PubMed Web of Science ®Google Scholar
• Hang MX, Blanchette VS, Pullenayegum E, et al. On behalf of the Canadian Hemophilia Primary Prophylaxis Study Group. Age at first joint bleed and bleeding severity in boys with severe hemophilia A: Canadian hemophilia primary prophylaxis study. J Thromb Haemost. 2011;9:1067–1069. doi: 10.1111/j.1538-7836.2011.04228.x
   PubMed Web of Science ®Google Scholar
• Wang M, Alvarez-Román MT, Chowdary P, et al. Physical activity in individuals with haemophilia and experience with recombinant factor VIII Fc fusion protein and recombinant factor IX Fc fusion protein for the treatment of active patients: a literature review and case reports. Blood Coagul Fibrinolysis. 2016;27:737–744. doi: 10.1097/MBC.0000000000000565
   PubMed Web of Science ®Google Scholar
• Goto M, Takedani H, Yokota K, et al. Strategies to encourage physical activity in patients with hemophilia to improve quality of life. J Blood Medicine. 2016;8:85–98. doi: 10.2147/JBM.S84848
   Web of Science ®Google Scholar
• van Os SB, Troop NA, Sullivan KR, et al. Adherence to prophylaxis in adolescents and young adults with severe haemophilia: A quantitative study with patients. PLoS ONE. 2017;12(1):e0169880, doi:10.1371/journal.pone.0169880.
   PubMed Web of Science ®Google Scholar
• Iorio A, Keepanasseril A, Foster G, et al. Development of a Web-Accessible Population Pharmacokinetic Service-Hemophilia (WAPPS-Hemo): Study Protocol. JMIR Res Protoc. 2016;5(4):e239. doi: 10.2196/resprot.6558
   PubMed Web of Science ®Google Scholar
• Collins PW, Quon DVK, Makris M, et al. Pharmacokinetics, safety and efficacy of a recombinant factor IX product, trenonacog alfa in previously treated haemophilia B patients. Haemophilia. 2017 Aug 17;24(1):104–112. [Epub ahead of print]. doi:10.1111/hae.13324.
   PubMed Web of Science ®Google Scholar
• Wu R, Luke KH. The benefit of low dose prophylaxis in the treatment of hemophilia: A focus on China. Expert Rev Hematol. 2017;10(11):995–1004. doi: 10.1080/17474086.2017.1386096
   PubMed Web of Science ®Google Scholar
• Wu R, Sun J, Xiao J, et al. A prospective study of health-related quality of life of boys with severe haemophilia A in China: comparing on-demand to prophylaxis treatment. Haemophilia. 2017;23(3):430–436. doi: 10.1111/hae.13198
   PubMed Web of Science ®Google Scholar
• Tang L, Wu R, Sun J, et al. Short-term low-dose secondary prophylaxis for severe/moderate haemophilia A children is beneficial to reduce bleed and improve daily activity, but there are obstacles in its execution: a multi-centre pilot study in China. Haemophilia. 2013;19(1):27–34. doi: 10.1111/j.1365-2516.2012.02926.x
   PubMed Web of Science ®Google Scholar
• Wu R, Luke KH, Poon MC, et al. Low dose secondary prophylaxis reduces joint bleeding in severe and moderate haemophilic children: a pilot study in China. Haemophilia. 2011;17(1):70–74. doi: 10.1111/j.1365-2516.2010.02348.x
   PubMed Web of Science ®Google Scholar
• Yao W, Xiao J, Cheng X, et al. The efficacy of recombinant FVIII low-dose prophylaxis in Chinese pediatric patients with severe hemophilia A. A retrospective analysis from the ReCARE Study. Clin Appl Thromb Haemost. 2017;23(7):851–858. doi: 10.1177/1076029616679507
   PubMed Web of Science ®Google Scholar
• Kavakli K, Yesilipek A, Antmen B, et al. The value of early treatment in patients with haemophilia and inhibitors. Haemophilia. 2010;16(3):487–494.
   PubMed Web of Science ®Google Scholar